ponatinib - Robuta Search

https://pubmed.ncbi.nlm.nih.gov/23691988/ Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study https://pubmed.ncbi.nlm.nih.gov/39506529/ Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the... The TOPASE study was set up to evaluate the outcomes of chronic myeloid leukaemia [CML] patients treated with ponatinib (PON) in a real-world setting in... https://www.iclusig.com/ ICLUSIG® (ponatinib) Treatment in CML and Ph+ ALL ICLUSIG is an FDA-approved prescription medication for adults with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic... ponatinib treatment cml ph https://stars.library.ucf.edu/etd2020/1295/ "BMP-7 Ameliorates Ponatinib Induced Muscle Cell toxicity: An in vitro " by Ayushi Srivastava Tyrosine Kinase Inhibitors associated muscle complaints like cramps, pain, and weakness are a few of the concerns contributing to declined disease control and... https://adisinsight.springer.com/trials/700362213?error=cookies_not_supported&code=75de5539-eafb-4e82-9276-5e32e6414a7c Evaluate the Real-World Safety Outcomes and Clinical Efficacy of Ponatinib and Other Tyrosine... The aims of this study are to learn out about treatment information (including amongst others treatment patterns, safety, development of a participant's the real world https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-ponatinib-newly-diagnosed-chronic-myeloid-leukaemia-epic A trial looking at ponatinib for people with newly diagnosed chronic myeloid leukaemia (EPIC) This trial was looking at ponatinib for people with newly diagnosed chronic myeloid leukaemia (CML) that is Philadelphia chromosome positive. https://www.sciencedaily.com/releases/2010/12/101206093713.htm Phase I trial indicates ponatinib may thwart most resistant chronic myeloid leukemia | ScienceDaily A new drug appears to help chronic myeloid leukemia patients who are out of treatment options after first- and second-line drugs have failed them or because... https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-ponatinib-chemotherapy-newly-diagnosed-philadelphia-chromosome FDA grants accelerated approval to ponatinib with chemotherapy for newly diagnosed Philadelphia... On March 19, 2024, the Food and Drug Administration granted accelerated approval to ponatinib (Iclusig, Takeda Pharmaceuticals U.S.A., Inc.) with chemotherapy f for newly diagnosed accelerated approval https://kohane.tch.harvard.edu/2026/04/22/polymeric-rapamycin-nanoparticles-encapsulating-ponatinib-cause-regression-of-venous-malformations-in-mice/ Polymeric Rapamycin Nanoparticles Encapsulating Ponatinib Cause Regression of Venous Malformations... Apr 22, 2026 - Tang W, Li Y, Boscolo E, Kohane DS*, Cullion K*: Polymeric Rapamycin Nanoparticles Encapsulating Ponatinib Cause Regression of Venous Malformations in Mice.... polymeric rapamycin nanoparticles encapsulating ponatinib